drugset / Trial / NCT00732485

Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate

NCT00732485

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Major burn injury causes significant insulin resistance on glucose and protein metabolism that persists for up to 6 months after the acute injury This project proposes to answer the following questions: 1. Will fenofibrate given to burn patients with insulin resistance restore their insulin sensitivity? 2. What is the relationship between mitochondrial dysfunction in muscle tissue as the causative mechanism of burn related insulin resistance? 3. To what extent will the restored insulin sensitivity affect glucose and protein metabolism in muscle, regenerating wounds and the liver, i.e. ameliorate burn related hyperglycemia and protein catabolism?

Timeline

Start
2008-08
Primary completion
2012-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fenofibrate Small molecule 5 mg/kg Oral

Indications

No indication recorded.